Membership

Currently, the ALLG has over 325 Members, including haematologists, medical oncologists, pathologists and scientists, located at more than 85 institutions in all states of Australia and all large cities of New Zealand.

The group also has more than 280 Associate Members, including data managers and research nurses, who participate in the clinical trials conducted by the ALLG.

The ALLG benefits from the commitment and expertise of its members in the medical and scientific communities.

Full Membership

Full membership of the ALLG is open to individuals who possess the qualifications and experience necessary to be a site or ALLG trial/study investigator and support the aims of the group. New Members must be personally recommended by two existing full ALLG Members who must be named as nominating members on the registration form. Full Members may choose that their membership be for a term of one, three or five years at a time.

Associate Membership

Associate Membership is available to individuals such as data managers, research nurses and trial coordinators who have an affiliation with the ALLG by virtue of their position of employment. The person must participate in a Study under the supervision of a Principal Investigator (PI). An Associate Member does not pay a membership fee, as such does not have Membership voting rights, and cannot be a PI of a clinical trial. An associate member is able to attend and participate in relevant ALLG meetings, receive notice of General Meetings, access relevant education and training opportunities.

Community Membership

Community membership is available to anyone who may be interested in the activities of the ALLG and would like to maintain an active intellectual interest in the group. It is hoped that a wide range of people will take advantage of this new way of being involved with the group and supporting its work. They may include:

  • Members upon retirement when they cease to be full members
  • Patients and their friends and family
  • People in the community who have been affected by a blood cancer
  • Members of consumer groups and patient advocates
  • Members of the public who wish to support research into blood cancers